Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells

Leukemia Research

Volumn 27, Issue 12, 2003, Pages 1135-1142

  Reid, Gregor S D ^a   Terrett, Luke ^a   Alessandri, Angela J ^b   Grubb, Stacey ^a   Stork, Linda ^c   Seibel, Nita ^d   Gaynon, Paul ^e   Schultz, Kirk R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Acute lymphoblastic leukemia; Costimulation; Cytokines; Immune response; Relapse; T cells

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; INTERLEUKIN 5; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH2 CELL;

EID: 0041561048     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00106-1     Document Type: Article

References (34)

1. Hasle H., Wadsworth L.D., Massing B.G., McBride M., Schultz K.R. A population-based study of childhood myelodysplastic syndrome in British Columbia. Br. J. Hematol. 106:1999;1027-1032.
2. Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents. United States SEER program 1975-1995. Bethesdea (MD): National Cancer Institute, SEER Program., NIH Pub. No. 99-4649; 1999.
3. Jiang Y.Z., Barrett A.J., Goldman J.M., Mavroudis D.A. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann. Hematol. 74:1997;1-6.
4. Faber L.M., van Luxemburg-Heijs S.A., Veenhof W.F., Willemze R., Falkenburg J.H. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood. 86:1995;2821-2828.
5. Passweg J.R., Tiberghien P., Cahn J.Y., Vowels M.R., Camitta B.M., Gale R.P.et al. Garft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. BMT. 21:1998;153-158.
6. Weisdorf D., Bishop M., Dharan B., Bolwell B., Cahn J.Y., Cairo M.et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol. Blood Marrow Transplant. 8:2002;213-220.
7. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E.et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6:2000;1018-1023.
8. Montagna D., Locatelli F., Calcaterra V., Comoli P., Moretta A., Giorgiani G.et al. Does the emergence and persistence of donor-derived leukemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. BMT. 22:1988;743-750.
9. Dermime S., Mavroudis D., Jiang Y.-Z., Hensel N., Molldrem J., Barrett A.J. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. BMT. 19:1997;989-999.
10. Cardoso A.A., Schultze J.L., Boussiotis V.A., Freeman G.J., Seamon M.J., Laszlo S.et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 88:1996;41-48.
11. Yotnda P., Mintz P., Grigoriadou K., Lemonnier F., Vilmer E., Langlade-Demoyen P. Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells. Exp. Hematol. 27:1999;1375-1383.
12. Matulonis U., Dosiou C., Freeman G., Lamont C., Mauch P., Nadler L.M.et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1996;1126-1131.
13. Matulonis U.A., Dosiou C., Lamont C., Freeman G.J., Mauch P., Nadler L.M. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 85:1995;2507-2515.
14. Cardoso A.A., Seamon M.J., Afonso H.M., Ghia P., Boussiotis V.A., Freeman G.J.et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 90:1997;549-561.
15. Dilloo D., Brown M., Roskrow M., Zhong W., Holladay M., Holden W.et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 90:1997;1927-1933.
16. Ghiac P., Transidico P., Veiga J.P., Schaniel C., Sallusto F., Matsushima K.et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 98:2001;533-540.
17. Yotnda P., Garcia F., Peuchmaur M., Grandchamp B., Duval M., Lemonnier F.et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102:1998;455-462.
18. Wallich R., Bulbuc N., Hammerling G.J., Katzav S., Segal S., Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H2K antigens following H-2 gene transfection. Nature. 315:1985;301-305.
19. Ostrand-Rosenberg S., Thakur A., Clements V.K. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:1990;4068-4071.
20. Restifo N.P., Esquivel F., Asher A.I., Stotter H., Barth R.J.et al. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J. Immunol. 147:1991;1453-1459.
21. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H.et al. Disease-associated bias in T helper type (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB1 × 0401+ patients with renal cell carcinoma or melanoma. J. Exp. Med. 196:2002;619-628.
22. Zheng P., Sarma S., Guo Y., Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res. 59:1999;3461-3466.
23. Alessandri A.J., Reid G.S.D., Bader S., Massing B.G., Sorensen P.H.B. ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukemia cells are associated with a distinct antigen-presenting phenotype. Br. J. Hematol. 116:2002;1-7.
24. Brouwer R.E., van der Heiden P., Schreuder G.M.T., Mulder A., Datema G., Anholts J.D.H.et al. Loss or downregulation of HLA Class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum. Immunol. 63:2002;200-210.
25. Wetzler M., Baer M.R., Stewart S.J., Donohue K., Ford L., Stewart C.C.et al. HLA class I cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and relapse. Leukemia. 15:2001;128-133.
26. Lowdell M.W., Craston R., Samuel D., Wood M.E., O'Neilll E.O., Saha V.et al. Evidence that continued remission in patients treated for acute leukemia is dependent upon autologous natural killer cells. Br. J. Hematol. 117:2002;821-827.
27. Ruggeri L., Capanni M., Casucci M., Volpi I., Tosti A., Perruccio K.et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 94:1999;333-339.
28. Reid G.S.D., Bharya S., Klingemann H.-G., Schultz K.R. Differential killing of pre-B acute lymphoblastic leukemia cells by activated NK cells and the NK-92ci cell line. Clin. Exp. Immunol. 129:2002;265-271.
29. Fallarino F., Grohmann U., Bianchi R., Vacca C., Fioretti M.C., Puccetti P. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J. Immunol. 165:2000;5495-5501.
30. Nagai H., Hara I., Horikawa T., Oka M., Kamidono S., Ichihashi M. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J. Invest. Dermatol. 115:2000;1059-1064.
31. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4+ T cells in the anti-tumor response. J. Exp. Med. 188:1998;2357-2368.
32. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:1999;617-627.
33. Zhang X.L., Komada Y., Chipeta J., Li Q.S., Inaba H., Azuma E.et al. Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia. Can. Immunol. Immunother. 49:2000;165-172.
34. Wang J., Shaw J.L., Mullen C.A. Down-regulation of antihost alloreactivity after bone marrow transplant permits relapse of hematological malignancy. Cancer Res. 62:2002;208-212.